UNSPSC 51112303: Improsulfan hydrochloride

This classification denotes an alkylsulfonate compound C8H19NO6S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GHX2MNT176, chemically known as 1-propanol, 3,3'-iminobis-, dimethanesulfonate (ester), hydrochloride, but more generally known as improsulfan hydrochloride, which bears US NIH Compound Identifier 18948. Most nations, for tariff and trade purposes, schedule improsulfan hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, IMPROSULFAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CS(=O)(=O)OCCCNCCCOS(=O)(=O)C.CL.

UNSPSC 51112303 Improsulfan hydrochloride is a Commodity code with minimal recent state and local procurement activity. The source records one opportunity—a Request for Information issued by the Texas Health and Human Services Commission in April 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—but this RFI seeks vendor capabilities and market intelligence on direct contracting mechanisms and pharmacy benefit administration rather than soliciting the product itself. The RFI does not position improsulfan hydrochloride as a named procurement target; instead, it gathers information about vendors' capacity to establish direct relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and wholesale channels. State and local buying under this Commodity code does not show sufficient recent activity to characterize issuing-body patterns or geographic concentration.

The Texas Health and Human Services Commission RFI, posted April 3, 2026, represents exploratory procurement activity rather than a formal competitive solicitation. No award value, budget range, set-aside designation, or binding response timeline was specified in the RFI materials, as the state was conducting foundational research on available solutions and vendor capabilities before issuing a formal Request for Proposal. The RFI's open-ended design suggests the state intends to gather information from a broad range of vendors interested in direct-to-manufacturer prescription programs and value-based contracting models. The absence of additional recent state and local opportunities under this code indicates either limited baseline demand for improsulfan hydrochloride specifically or a pattern in which state and local pharmaceutical purchases are tagged to broader pharmacy-supply codes rather than individual-drug Commodities.